Several studies have demonstrated that administration of cholecystokinin ( CCK) reduces food intake in several species, including humans. In animal studies CCK-receptor antagonists have been reported to increase food intake, suggesting a physiological satiety effect of CCK in these animals. In a double-blind, placebo-controlled study, we investigated the effect of the specific CCK-A receptor antagonist loxiglumide on food intake (carbohydrate-rich meal) and on subjective hunger feelings scored with visual analogue scales and food selection lists in seven healthy obese women and in seven healthy lean women. Loxiglumide was administered intrave nously in a dose o f 10 mg/kg ideal weight/h. For the whole group, food intake during loxiglu mide (359 ± 39 g ) was not significantly different from food intake during saline infusion (333 ± 31 g). Also, when the lean and obese subgroups were analyzed separately, no significant influence of loxiglumide on food intake was found. In addition, no significant differences in satiety scores were seen using the food selection lists or visual analogue scales. In conclusion, in the present study during infusing the CCK-A receptor antagonist loxiglumide we found no increase in preprandial satiety nor in food intake of a carbohydrate-rich meal nor in postpran dial satiety in lean and obese women.
Introduction
Cholecystokinin (CCK) was identified from preparations of intestinal extracts by its ability to stimulate gallbladder con traction (Liddle 1989). Several other biological actions of CCK have subsequently been identified, like stimulation of pancreatic exocrine enzyme secretion, inhibition of gastric emptying, influences on intestinal motility, and effects on 332 BIOL PSYCHIATRY 1995; 37:331-335 
Materials and Methods
Seven healthy obese women (mean age 43 ± 3 yr, mean body mass index 39 ± 2 kg/m2) and seven healthy lean women (mean age 42 ± 3 yr, mean body mass index 22 ± 0.3 kg/m2) were studied. Informed consent was obtained from all subjects. The protocol had been approved by the local human ethics committee.
After an overnight fast, the volunteers presented at our laboratory at 08.00 h. An intravenous cannula was inserted into the antecubital vein o f one arm for infusion of loxiglu mide or saline (placebo). Saline or loxiglumide 10 mg/kg ideal weight/h (Rotta Research Laboratories, Monza, Italy) was infused through an intravenous catheter for 165 min, in random order and double blinded. In obese persons the ideal weight was calculated by subtracting 100 from their body length in cm (Broca weight) (Kelke et al 1992), while for lean subjects their actual weight was used. We have shown in previous investigations that this calculation used for the infusion of gastrointestinal hormones such as CCK results in comparable plasma hormone levels between lean and obese subjects (Lieverse et al 1993). The infusions were started at 09.00 h. The two studies were separated from each other by an interval o f at least 1 week. The investigations were performed irrespective o f the time of the menstrual cycle. Sixty minutes after the start of the saline or loxiglu mide infusion, a banana shake consisting of 100 g of bana nas (132 kcal), supplemented with water to 300 ml and blended, was served and consumed within 3 minutes. Fif teen minutes later, at time 75 min, a solid meal of banana slices containing 1 g/100 g of protein, 0 g/100 g of fat, and 32 g/100 g o f carbohydrates was offered in abundance. The meal was weighed before and after consumption to deter mine the exact amount of food consumed.
Subjective criteria like the wish to eat, hunger feeling, fullness, and prospective feeding intentions were scored on 100-mm visual analogue scales (Blundell and Burley 1987; Silverstone 1982) . These criteria were assessed basally and at 15 -min interval until 60 min after the end of the infusion period. The following questions were asked: How strong is your wish to eat? (from very weak to very strong). How hungry do you feel? (from not hungry at all to as hungry as I have ever felt). How full do you feel? (from not full at all to very full).
How much food do you think you could eat? (from nothing to very much).
In addition, the subjects also indicated on visual analogue scales whether they appreciated the meal and whether they experienced nausea. Subjective hunger feelings were also measured with food selection lists, as described by Hill (1987) and modified for Dutch feeding customs. Each food selection list was accompanied by a photograph showing 6 protein-rich, 6 fat-rich, 6 carbohydrate-rich (each about 200 kcal) and 6 low-energy items. For each of these 24 items, the subjects were asked if they wanted to eat the item at that moment and to indicate the amount, double the amount, half the amount, or nothing of the item they wished to consume. Every item was scored independent of the other items. Sub jects were presented with a food-selection list 15 min before the infusion, 15 min before the banana shake (at time 45 min), 15 min after the meal (at time 90 min), and at time 120 min, time 165 min (end of the infusion), and time 225 min (end of the experiment). Every time the list was presented, the total amount of caloric items was calculated (half the amount = 1/2 caloric item, double the amount = 2 caloric items).
Statistical A nalysis
Results are given as mean ± SEM. Statistical analysis of hunger feelings was performed by calculating the incre mental integrated area under the curve (AUC) before and after the meal, followed by Wilcoxon matched pairs signed rank test. Food intake was compared using Wilcoxon matched pairs signed rank test. Differences between lean and obese subjects were analyzed using Mann-Whitney test. The significance level was set atp < .05.
Results
For the whole group (obese and lean women together) food intake was not significantly different between the loxiglu mide experiment (359±39 g) and the control experiment (333 ± 31 g). Neither was food intake significantly different between the loxiglumide and control experiment in the lean subjects (405 ± 56 g vs. 365 ± 42 g, respectively) nor in the obese subjects (313 ± 54 g vs. 301 ± 45 g, respectively; Figure 1 ). No significant differences were seen between loxiglumide and saline infusion using the food selection lists or the visual analogue scales (Table 1, Figure 2) . Look ing at lean and obese subjects separately, there was a de crease in prospective feeding intentions in the lean group during loxiglumide (p = .028, Table 1 ). There was a signifi cant greater postprandial satiety effect (p < .01) during loxiglumide in the obese than in the lean individuals for wish to eat (p = .006), hunger feelings (p = .009), and fullness (p = .003) ( Table 1) . No other significant differ ences between loxiglumide and saline or between obese and lean subjects were found (Table 1) . ate as long during loxiglumide (6.4 ± 0.8 min) as during saline (6.1 ± 0.6 min). No nausea during any study w as recorded in lean or obese subjects.
Discussion
In contrast to studies in several animal species, w e did not observe a significant increase in food intake during admin istration of the potent and specific CCK-A receptor antago nist loxiglumide in humans. Neither in the obese nor in the lean women was there a significant difference in food intake between the loxiglumide and the control experiment. In addition, we found no increase in preprandial or postpran dial subjective hunger feelings during loxiglum ide admin istration compared to placebo.
Recently, Wolkowitz et al observed in eight healthy m ale volunteers a significant increase in hunger feelings with MK-329, another CCK-A antagonist (W olkowitz et al 1990), whereas we found no significant increase in hunger sensations. The cause of this difference is not apparent, but it may be related to differences in study protocols. First, in the study of Wolkowitz et al the CCK-A receptor antagonist was administered orally, whereas in our study the CCK-A Table 1 Both lean and obese subjects liked bananas equally (59 ± 9 and 65 ± 7 mm, respectively, on 100-mm visual analogue scales). The duration of the meal was significantly shorter with loxiglumide (5.1 ± 0.6 min) for obese subjects than during saline (7.3 ± 0.8 min, p < .05), whereas lean subjects The results of our study are in agreement with those of Drewe et al (1992), who found no influence of loxiglumide on hunger feelings or food intake in lean, healthy subjects. That study, however, was performed with an intraduodenal tube in situ; it cannot be excluded that the duodenal intuba tion may have adversely affected the results. A more likely explanation for the fact that we did not observe a significant increase in food intake or in postprandial hunger feelings during loxiglumide administration may be related to the composition of the meal. In our study we offered a carbohy drate-rich meal that does not release endogenous CCK. It is well known that fat and protein, but not carbohydrates, are potent stimuli of CCK secretion. It therefore remains possi ble that blockade of CCK-A receptors increases food intake when a protein or fat meal, which induces CCK release, is consumed. In further studies evaluating the effect of CCK-intake * --------1---------------------»wwv. im ujvu m n u iu a u ö , »peu attention should be drawn to the composition of the meal. 
